Role of Peripheral Benzodiazepine Receptors in Mitochondrial, Cellular, and Cardiac Damage Induced by Oxidative Stress and Ischemia-Reperfusion

  1. Nathalie Leducq,
  2. Françoise Bono,
  3. Thierry Sulpice,
  4. Val érie Vin,
  5. Philip Janiak,
  6. Gérard Le Fur,
  7. Steve E. O'Connor and
  8. Jean-Marc Herbert
  1. Sanofi∼ Synthélabo Research, Toulouse and Chilly-Mazarin, France
  1. Address correspondence to:
    Dr. J. M. Herbert, Cardiovascular-Thrombosis Research Department, Sanofi-Synthélabo Research, 195, Route d'Espagne, 31036 Toulouse, France. E-mail: jean-marc.herbert{at}sanofi-synthelabo.com

Abstract

Mitochondrial dysfunction has been identified as a possible early event in ischemia-reperfusion damage. The peripheral benzodiazepine receptor, a mitochondrial inner membrane protein, has already been proposed to play a role in mitochondrial regulation, although its exact function remains unclear. The aim of this work was to determine the role of peripheral benzodiazepine receptor in ischemia-reperfusion injury and to test the potential beneficial effect of a novel potent peripheral benzodiazepine receptor ligand, 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide (SSR180575). To characterize and link the mitochondrial, cellular, and cardiac consequences of ischemia-reperfusion, we examined the effects of SSR180575 in several in vitro and in vivo models of oxidative stress. Hydrogen peroxide decreased mitochondrial membrane potential, reduced oxidative phosphorylation capacities, and caused cytochrome c release, caspase 3 activation, and DNA fragmentation. SSR180575 (100 nM-1 μM) prevented all these effects. In perfused rat hearts, SSR180575 administered in vitro (100 nM-1 μM) or by oral pretreatment (3-30 mg/kg) greatly reduced the contractile dysfunction associated with ischemia-reperfusion. Furthermore, in anesthetized rats, SSR180575 (3-30 mg/kg p.o.) produced significant reductions in infarct size after coronary artery occlusion/reperfusion. In conclusion, we have demonstrated that peripheral benzodiazepine receptor play a major role in the regulation of cardiac ischemia-reperfusion injury and that SSR180575, a novel peripheral benzodiazepine receptor ligand, is of potential interest in these indications.

Footnotes

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • DOI: 10.1124/jpet.103.052068.

  • ABBREVIATIONS: ROS, reactive oxygen species; MPT, mitochondrial permeability transition; PBR, peripheral benzodiazepine receptor; TES, 2-{[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino}ethanesulfonic acid; BSA, bovine serum albumin; PBS, phosphate-buffered saline; HA, hemagglutinin; HEK, human embryonic kidney; MEM, minimal essential medium; FITC, fluorescein isothiocyanate; LVDP, left ventricular developed pressure; HR, heart rate; AAR, area at risk of infarction; WT, wild type; SSR180575, 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide; PK11195, 1-(2-chloro-phenyl)-N-methyl-N-(1-methylpropyl)-1-isoquinoline carboxamide; Ro5-4864, 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepine-2-one.

    • Received March 31, 2003.
    • Accepted May 12, 2003.
« Previous | Next Article »Table of Contents